Organisation paid for research Program year 2025 Source: CMS Open Payments

Cleaver Medical Group

Neither a doctor nor a teaching hospital

Research payments

$165,828

61 payments

Through program year 2025, Cleaver Medical Group is reported as receiving $165,828 in research payments, across 61 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $111,754 44
2024 Research $53,156 12
2023 Research $918 5

Breakdown

Who paid Research payments · program years 2023–2025
  1. Incyte Corporation $145,339 58 payments
  2. AbbVie, Inc. $14,264 2 payments
  3. Novartis Pharmaceuticals Corporation $6,225 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $54,074 17 payments
  2. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $41,323 24 payments
  3. A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis $29,812 12 payments
  4. A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo $20,130 5 payments
  5. A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata $11,906 1 payment
  6. A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $6,225 1 payment
  7. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy $2,358 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record